Search for content, post, videos

Annexin appoints Jamal El-Mosleh as new CEO

Jamal El Mosleh

Annexin Pharmaceuticals has appointed Jamal El-Mosleh as new CEO of the company, and he started his new position on October 16th.

Jamal El-Mosleh has a MSc in Industrial Economics with focus on biotechnology from the Chalmers University of Technology and a Master from Chalmers School of Entrepreneurship (Biotechnology). He has previously had a position as CEO for Immunicum, where he worked 2007-2016. He was a driving force in Immunicum’s entry on the stock exchange and he took the company’s leading product candidate from idea to an extensive international clinical program with several indications.